バイオ医薬品市場：製品タイプ、サービス、原料タイプ、用途別-2024～2030年の世界予測

バイオ医薬品市場規模は2023年に5,740億4,000万米ドルと推定され、2024年には6,271億9,000万米ドルに達すると予測され、CAGR 9.74%で2030年には1兆1,005億1,000万米ドルに達すると予測されます。

バイオ医薬品は生物製剤とも呼ばれ、バイオテクノロジーを利用して製造される医療用医薬品を指します。タンパク質や核酸から構成され、治療や診断の目的で使用されます。化学的に合成され、明確な分子構造を持つ従来の医薬品とは異なり、バイオ医薬品は生物に由来します。これらの生物には、ホルモン、抗体、ワクチンなど、目的の治療物質を産生するように遺伝子操作された細菌、酵母、哺乳類細胞などが含まれます。がん、心血管疾患、結核、クローン病、関節炎などの慢性疾患や感染症の増加により、新規のバイオ医薬品に対するニーズが高まっています。さらに、ヘルスケア・インフラの拡大、ヘルスケア・サービスへのアクセスの増加、新薬の発見と開発を促進する政府の支援策が、業界の成長をさらに生み出しています。しかし、温度に敏感な製品のコールドチェーンロジスティクスを維持することは、バイオ医薬品にとってハードルとなります。さらに、製造工程が複雑であることも、業界の広範な成長を大きく阻害する可能性があります。しかし、主要企業はAI/MLやデータ分析などの新技術に投資し、バイオ医薬品の生産を合理化・加速しています。さらに、個別化医療の採用とゲノム研究の進歩は、業界の成長に新たな機会を創出する可能性があります。

製品タイプモノクローナル抗体分野のイノベーションを促進する継続的な研究開発イニシアティブ

モノクローナル抗体（mAbs）は、有害な病原体を撃退する免疫系の能力を模倣したタンパク質です。モノクローナル抗体は、がん細胞の表面にあるような特定の抗原をターゲットにカスタムデザインされています。精製されたタンパク質には、酵素、ホルモン、その他治療作用のあるタンパク質が含まれます。これらのタンパク質は、酵素障害、ホルモン欠乏症、その他天然タンパク質の補充が必要な疾患の治療に使用されます。組換え成長因子は、細胞の成長、増殖、治癒、細胞分化を刺激するタンパク質です。好中球減少症や創傷治癒など、様々な医療治療に広く用いられています。遺伝子組換えホルモンは、ヒトの体内で自然に産生されるホルモンと同じものを遺伝子工学的に作製したもので、インスリン、ヒト成長ホルモン、エリスロポエチンなどが代表的です。遺伝子組換え蛋白質は、酵素、サイトカイン、血液因子など幅広い生物学的に活性な蛋白質で、遺伝子組換えDNA技術を用いて製造されます。合成免疫調節薬は、免疫反応を増強または抑制することにより、免疫反応を変化させることができる薬剤です。自己免疫疾患やがんの治療、臓器移植に用いられます。病気の治療や臓器移植における拒絶反応の予防のために免疫系の調節が必要な場合には、合成免疫調節剤が好まれます。ワクチンは生物学的製剤であり、特定の感染症に対する能動的獲得免疫の獲得を目的とします。ワクチンには、病原微生物、その毒素、またはその表面タンパク質の1つが、弱毒化または死滅した状態で含まれています。

サービス規制遵守を確実にするためのコンペンデンシャル＆マルチコンペンデンシャル・ラボ試験の必要性

バイオ医薬品業界では、米国薬局方（USP）、欧州薬局方（EP）、日本薬局方（JP）など、さまざまな薬局方の厳格な基準や規制を製品が満たしていることを確認するために、コンペンディアル＆マルチコンペンディアル試験室検査サービスが不可欠です。これらの試験は品質管理のために必要であり、バイオ医薬品の安全性、衛生性、有効性、品質を市場に出る前に保証するものです。カスタム試験または顧客独自の試験は、バイオ医薬品会社独自のニーズに合わせて調整されます。確立されたガイドラインに従ったコンペンデンシャル試験とは異なり、カスタム試験は、企業独自の製品やプロセスのために特別に開発されます。これには、安定性試験、試験法の開発、バリデーション、標準的なコンペンデンシャル試験法ではカバーできない不純物の試験などが含まれます。より広い意味でのラボ試験には、バイオ医薬品が必要な品質基準や規制を遵守していることを確認するために実施される様々なタイプの分析が含まれます。これには、バイオ分析サービス、微生物学的評価、環境モニタリングなどが含まれるが、これらに限定されるものではないです。

原材料の種類：病状を診断、治療、緩和するための強力なAPI開発への取り組み

医薬品有効成分（API）は、意図した効果をもたらす医薬品の主要成分です。APIは新薬の製剤開発にとって極めて重要であり、バイオ医薬品の創出において重要な役割を果たしています。原薬は有効性と安全性を確保するために高度に規制されています。低用量を必要とする治療では高活性の原薬が好まれることが多く、慢性疾患では安定したコスト効率の良い供給が鍵となります。製剤賦形剤とは、強力な有効成分を少量含む製剤を増量したり、薬物の吸収や安定性を促進するなど治療効果を高める目的で使用される不活性物質です。賦形剤の選択は、ドラッグデリバリーの方法、要求される剤形、安定性の要件に依存します。賦形剤は原薬と適合性があり、医薬品の有効性や安全性プロファイルに影響を及ぼさないものでなければならないです。

応用：心血管疾患の治療戦略の必要性につながるライフスタイルの変化

自己免疫疾患に使用されるバイオ医薬品は、多くの場合、免疫系が患者自身の細胞を攻撃するのを防ぐために、免疫系を調節することに焦点を当てています。これらの薬剤は、関節リウマチ、ループス、1型糖尿病などの疾患にとって極めて重要です。バイオ医薬品は、心不全、高コレステロール血症、高血圧などの状態を管理するのに役立つ治療法を提供することで、心血管疾患に対処します。糖尿病や甲状腺機能障害などのホルモン疾患は、ホルモンレベルの補充や調整を目的としたバイオ医薬品によって管理されます。免疫学のバイオ医薬品は通常、特定の免疫細胞や免疫経路を標的とすることで、免疫介在性疾患を治療するように設計されています。全身的な免疫抑制を軽減する標的療法は、感染症のリスクを減らすために好ましいです。炎症性・感染性疾患のバイオ医薬品には、従来の低分子治療薬の有効性を改善しようとする抗生物質や抗炎症薬が含まれます。潜在的な副作用や毒性を最小限に抑えながら、薬剤耐性を克服できる治療法に焦点が当てられています。代謝性疾患に合わせたバイオ医薬品は、肥満、骨粗鬆症、脂質異常症などの疾患の治療法を提供します。代謝性疾患の管理と同時に、心血管イベントのリスクを軽減できるバイオ医薬品は高く評価されています。酵素補充療法やモノクローナル抗体などのバイオ医薬品は、多発性硬化症（MS）やアルツハイマー病などの神経疾患を対象としています。血液脳関門（BBB）を通過することができ、神経炎症に対する調節効果を提供する治療薬が必要とされています。がん治療におけるバイオ医薬品の使用は、がん細胞を特異的に標的とし、免疫系を調節して病気と闘うことができる薬剤によって、がん治療のいくつかの改善を促しています。

地域別の洞察

南北アメリカ地域、特に米国とカナダは、強固な知的財産権、科学主導の規制枠組み、競合市場競争状況の組み合わせに後押しされ、バイオ医薬品の研究開発において高度な先進地域であり続けています。米国食品医薬品局（FDA）は、技術革新の急速なペースに絶えず適応し、安全で効果的な治療法が確実に患者に届くようにしています。バイオテクノロジー分野の主要企業が複数存在し、償還や健康保険を提供する強固なヘルスケア・インフラが整っていることが、バイオ医薬品産業の成長につながっています。EU地域は、ライフサイエンスとバイオテクノロジーの分野における研究開発の強固な地盤を誇っています。バイオ医薬品の開発に関する厳しい規制や基準が、バイオ医薬品のイノベーションのための標準化、体系化された安全な環境を作り出しています。EUの欧州医薬品庁（EMA）は、新しい治療法の開発と利用を促進する上で中心的な役割を果たしています。強力な官民パートナーシップとヘルスケア・イノベーションへのコミットメントが、EUの消費者ニーズと行動を規定し、高品質で持続可能なヘルスケアソリューションに傾いています。APAC地域では、高齢化が進み、手頃な価格のヘルスケアサービスへのアクセスを促進するための政府のインセンティブやイニシアチブが、バイオ医薬品の必要性につながっています。製薬部門が確立している日本は、ヘルスケア・ソリューションへの支出が大きいという特徴があります。インドや中国などのAPAC地域の国々は、バイオ医薬品の費用対効果の高い製造に重点を置いており、バイオシミラー製造に投資することが多いです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはバイオ医薬品市場を評価する上で極めて重要です。事業戦略や製品満足度に関する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、バイオ医薬品市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.バイオ医薬品市場の市場規模および予測は？

2.バイオ医薬品市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.バイオ医薬品市場の技術動向と規制枠組みは？

4.バイオ医薬品市場における主要ベンダーの市場シェアは？

5.バイオ医薬品市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延とターゲットを絞った治療の必要性バイオ医薬品
    • ワクチンと医薬品開発への投資増加
    • バイオ医薬品の魅力的な償還ポリシー
  • 抑制要因
    • 原材料サプライチェーンの混乱と医薬品開発の高コスト
  • 機会
    • バイオ医薬品の製造および試験技術の進歩
    • バイオ医薬品とワクチン製造のアウトソーシングの新たな動向
  • 課題
    • 医薬品製造と時間のかかる臨床試験に対する厳格な規制枠組み
• 市場セグメンテーション分析
  • 製品タイプ：モノクローナル抗体分野におけるイノベーションを促進するための継続的な研究開発イニシアチブ
  • サービス：規制への準拠を確保するための公定書および複数の公定書の試験所試験の必要性
  • 原材料の種類：病気の診断、治療、緩和のための強力なAPIの開発への取り組み
  • 応用：ライフスタイルの変化による心血管疾患の治療戦略の必要性
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 バイオ医薬品市場：製品タイプ別

• モノクローナル抗体
• 精製タンパク質
• 組み換え成長因子
• 組み換えホルモン
• 組み換えタンパク質
• 合成免疫調節剤
• ワクチン

第7章 バイオ医薬品市場：サービス別

• 公定書およびマルチ公定書のラボ試験
• カスタムテストまたは顧客独自のテスト
• 臨床検査

第8章 バイオ医薬品市場原材料の種類別

• 有効医薬品成分
• 製剤添加剤

第9章 バイオ医薬品市場：用途別

• 自己免疫疾患
• 心血管疾患
• ホルモン障害
• 免疫学
• 炎症性疾患および感染症
• 代謝障害
• 神経疾患
• 腫瘍学

第10章 南北アメリカのバイオ医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のバイオ医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのバイオ医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • アストラゼネカ、RSウイルスワクチン開発企業イコサバックスを11億米ドルで買収へ
  • アルツハイマー病治療薬「LEQEMBI点滴静注（レカネマブ）」12月20日に日本で発売
  • HHS、命を救うモノクローナル抗体の開発に向けたリジェネロンとの提携の詳細を発表

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BIOPHARMACEUTICALS MARKET RESEARCH PROCESS
• FIGURE 2. BIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BIOPHARMACEUTICALS MARKET DYNAMICS
• FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT HORMONE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT HORMONE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SYNTHETIC IMMUNOMODULATORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SYNTHETIC IMMUNOMODULATORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COMPENDIAL & MULTI COMPENDIAL LABORATORY TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COMPENDIAL & MULTI COMPENDIAL LABORATORY TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CUSTOM TESTING OR CUSTOMER PROPRIETARY TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CUSTOM TESTING OR CUSTOMER PROPRIETARY TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY FORMULATION EXCIPIENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY FORMULATION EXCIPIENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY & INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY & INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 65. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 66. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 82. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 83. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 84. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 85. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 86. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 87. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 90. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 98. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 108. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 110. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 117. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 118. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 119. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 120. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 121. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 122. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 126. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 127. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 128. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 129. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 130. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 131. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. CHINA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 134. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 135. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 136. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 137. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 138. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 139. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. INDIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 142. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 143. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 144. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 145. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 146. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 147. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. INDONESIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 150. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 151. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 152. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 153. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 154. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 155. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. JAPAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 158. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 159. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 160. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 161. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 162. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 163. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. MALAYSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 166. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 167. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 168. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 169. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 170. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 171. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. PHILIPPINES BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 174. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 175. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 176. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 177. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 178. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 179. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. SINGAPORE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 182. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 184. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 186. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 190. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 191. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 192. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 193. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 194. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 195. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. TAIWAN BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 198. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 199. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 200. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 201. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 202. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 203. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 204. THAILAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 205. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 206. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 207. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 208. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 209. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 210. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 211. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. VIETNAM BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 223. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 224. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 225. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 226. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 227. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 228. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 229. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 230. DENMARK BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 231. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 232. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 233. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 234. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 235. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 236. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 237. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. EGYPT BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 240. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 241. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 242. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 243. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 244. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 245. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. FINLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 248. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 249. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 250. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 251. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 252. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 253. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 254. FRANCE BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 255. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 256. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 257. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 258. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 259. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 260. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 261. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 264. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 265. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 266. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 267. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 268. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 269. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. ISRAEL BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 272. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 273. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 274. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 275. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 276. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 277. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 278. ITALY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 279. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 280. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 281. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 282. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 283. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 284. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 285. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. NETHERLANDS BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 288. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 289. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 290. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 291. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 292. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 293. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 294. NIGERIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 295. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 296. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 297. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 298. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 299. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 300. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 301. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 302. NORWAY BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 303. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 304. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 305. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 306. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 307. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 308. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 309. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 310. POLAND BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 311. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 312. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 313. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 314. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 315. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 316. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 317. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 318. QATAR BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 319. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 320. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 321. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 322. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 323. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 324. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 325. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 326. RUSSIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 327. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 328. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 329. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 330. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 331. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 332. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 333. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 334. SAUDI ARABIA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 335. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 336. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 337. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 338. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 339. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2018-2023 (USD MILLION)
• TABLE 340. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RAW MATERIAL TYPE, 2024-2030 (USD MILLION)
• TABLE 341. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 342. SOUTH AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 343. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2023 (USD MILLION)
• TABLE 344. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024-2030 (USD MILLION)
• TABLE 345. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 346. SPAIN BIOPHARMACEUTICALS MARKET SIZE, BY SERVICES,

[191 Pages Report] The Biopharmaceuticals Market size was estimated at USD 574.04 billion in 2023 and expected to reach USD 627.19 billion in 2024, at a CAGR 9.74% to reach USD 1,100.51 billion by 2030.

Biopharmaceuticals, also known as biologics, refer to medical drugs produced using biotechnology. They are comprised of proteins and nucleic acids and are used for therapeutic or diagnostic purposes. Unlike traditional pharmaceuticals, which are chemically synthesized and have well-defined molecular structures, biopharmaceuticals are derived from living organisms. These organisms can include bacteria, yeast, or mammalian cells that are genetically engineered to produce the desired therapeutic substances, such as hormones, antibodies, or vaccines. The rising incidences of chronic and infectious diseases such as cancer, cardiovascular disorders, tuberculosis, Crohn's disease, and arthritis have created a need for novel biopharmaceuticals. Additionally, the expansion of healthcare infrastructure, growing access to healthcare services, and supportive government initiatives that promote the discovery and development of new pharmaceuticals have further generated growth for the industry. However, maintaining cold chain logistics for temperature-sensitive products can prove to be a hurdle for biopharmaceuticals. Furthermore, complexities in manufacturing processes can also significantly impede the widespread growth of the industry. However, key players are investing in new technologies such as AI/ML and data analytics to streamline and accelerate the production of biopharmaceuticals. Moreover, the adoption of personalized medicine and advancement in genomic research can create new opportunities for the growth of the industry.

Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies

Monoclonal antibodies (mAbs) are proteins that mimic the immune system's capacity to fight off harmful pathogens. They are custom-designed to target specific antigens, such as those found on the surface of cancer cells. Purified proteins include enzymes, hormones, and other proteins that have therapeutic action. These proteins are employed in the treatment of enzymatic disorders, hormonal deficiencies, and other conditions where supplementation of natural proteins is needed. Recombinant growth factors are proteins that stimulate cellular growth, proliferation, healing, and cellular differentiation. They are widely used in various medical treatments, including neutropenia and wound healing. Recombinant hormones are genetically engineered hormones identical to those produced naturally in the human body, most commonly insulin, human growth hormone, and erythropoietin. Recombinant proteins cover a broad range of biologically active proteins, including enzymes, cytokines, and blood factors, manufactured using recombinant DNA technology. Synthetic Immunomodulators are agents that can modify the immune response by enhancing or suppressing it. They're used in treating autoimmune diseases and cancers and in organ transplantation. They are preferred when modulation of the immune system is necessary to treat disease or prevent rejection in organ transplant scenarios. Vaccines are biological preparations that aim to provide active acquired immunity to particular infectious diseases. They can contain live attenuated or killed forms of the pathogenic microorganism, its toxins, or one of its surface proteins.

Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations

In the biopharmaceutical industry, compendial & multicompendial laboratory testing services are essential for ensuring that products meet the strict standards and regulations of various pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopeia (EP), or Japanese Pharmacopeia (JP). These tests are required for quality control and to ensure the safety, hygiene, efficacy, and quality of biopharmaceuticals before they reach the market. Custom testing or customer proprietary testing is tailored to meet the unique needs of a biopharmaceutical company. Unlike compendial testing, which follows established guidelines, custom testing is developed specifically for a company's proprietary products or processes. This can include stability testing, method development, validation, or testing for impurities that are not covered by standard compendial methods. Laboratory testing, in a broader sense, encompasses various types of analyses performed to ensure that biopharmaceutical products adhere to all necessary quality standards and regulations. This can extend from raw material testing to final product release testing, including but not limited to bioanalytical services, microbiological evaluation, and environmental monitoring.

Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions

The active pharmaceutical ingredient (API) is the primary component of any drug product that produces the intended effects. APIs are crucial for the development of new drug formulations and play a significant role in the creation of biopharmaceutical products. They are highly regulated to ensure efficacy and safety. Highly potent APIs are often preferred in treatments requiring lower dosage, while for chronic conditions, consistent and cost-effective supply is key. Formulation excipients are inactive substances used for the purpose of bulking up formulations that contain potent active ingredients in small amounts or to confer a therapeutic enhancement, such as facilitating drug absorption or stability. The choice of excipients is dependent on the drug's delivery method, the required dosage form, and stability requirements. Excipients must be compatible with the API and should not affect the drug's efficacy or safety profile.

Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases

The biopharmaceuticals used for autoimmune disorders often focus on the modulation of the immune system to prevent it from attacking the patient's own cells. These medications are crucial for conditions such as rheumatoid arthritis, lupus, and type 1 diabetes. Biopharmaceuticals address cardiovascular diseases by offering treatments that can help manage conditions such as heart failure, hypercholesterolemia, and hypertension. Hormonal disorders such as diabetes and thyroid dysfunctions are managed through biopharmaceuticals that aim to replace or regulate hormone levels. Biopharmaceuticals in immunology are typically designed to treat immune-mediated diseases by targeting specific immune cells or pathways. Targeted therapies that reduce systemic immunosuppression are preferred to decrease the risk of infections. Biopharmaceuticals for inflammatory and infectious diseases include antibiotics and anti-inflammatory drugs that seek to improve upon the efficacy of traditional small-molecule treatments. The focus is on treatments that can overcome drug resistance while minimizing potential side effects and toxicity. Biopharmaceuticals tailored for metabolic disorders offer treatments for diseases such as obesity, osteoporosis, and dyslipidemia. Biopharmaceuticals that can reduce the risk of cardiovascular events alongside managing metabolic disorders are highly valued. Biopharmaceuticals in the form of enzyme replacement therapies and monoclonal antibodies target neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease. Therapeutics that are able to cross the blood-brain barrier (BBB) and offer modulatory effects on neuroinflammation are in need. The use of biopharmaceuticals in oncology has driven several improvements in cancer treatment, with drugs that can specifically target cancer cells and modulate the immune system to combat the disease.

Regional Insights

The Americas region, particularly the U.S. and Canada, remains a highly advanced region in biopharmaceutical research and development, spurred by a combination of robust intellectual property rights, a science-driven regulatory framework, and a competitive market landscape. The U.S. Food and Drug Administration (FDA) continuously adapts to the rapid pace of innovation, ensuring safe and effective treatments reach patients. The presence of several key players in the biotechnological sector and a robust healthcare infrastructure that provides reimbursements and health insurance have led to the growth of the biopharmaceutical industry. The EU region boasts a robust ground for research and development in the sphere of life sciences and biotechnology. Stringent regulations and standards pertaining to the development of biopharmaceuticals have created a standardized, systematic, and safe environment for innovations in biopharmaceuticals. The European Medicines Agency (EMA) in the EU plays a central role in facilitating the development and accessibility of new therapies. Strong public-private partnerships and a commitment to healthcare innovation define the EU's consumer needs and behavior, which lean towards high-quality, sustainable healthcare solutions. In the APAC region, a growing aging population and government incentives and initiatives for promoting access to affordable healthcare services have led to a need for biopharmaceuticals. Japan, with its established pharmaceutical sector, is characterized by significant spending on healthcare solutions. Countries in the APAC region, such as India and China, have focused on the cost-effective manufacturing of biopharmaceuticals and often invest in biosimilar production.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biopharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Abgenex, Amgen Inc., AstraZeneca PLC, Avidea Technologies, Bayer AG, Bio-Techne Corporation, Biogen Inc., bioMerieux SA, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., LG Chem Life Sciences Innovation Center, Inc., Merck & Co., Inc., Nordic BioSite, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product Type
  • Monoclonal Antibodies
  • Purified Proteins
  • Recombinant Growth Factors
  • Recombinant Hormone
  • Recombinant Proteins
  • Synthetic Immunomodulators
  • Vaccines

• Services
  • Compendial & Multi Compendial Laboratory Testing
  • Custom Testing or Customer Proprietary Testing
  • Laboratory Testing

• Raw Material Type
  • Active Pharmaceutical Ingredient
  • Formulation Excipients

• Application
  • Autoimmune Disorders
  • Cardiovascular Diseases
  • Hormonal Disorders
  • Immunology
  • Inflammatory & Infectious Diseases
  • Metabolic Disorders
  • Neurological Diseases
  • Oncology

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biopharmaceuticals Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biopharmaceuticals Market?

3. What are the technology trends and regulatory frameworks in the Biopharmaceuticals Market?

4. What is the market share of the leading vendors in the Biopharmaceuticals Market?

5. Which modes and strategic moves are suitable for entering the Biopharmaceuticals Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
    • 5.1.1.2. Rising Investments in Vaccine and Drugs Development
    • 5.1.1.3. Attractive Reimbursement Policies for Biopharmaceuticals
  • 5.1.2. Restraints
    • 5.1.2.1. Raw Material Supply Chain Disruptions and High Cost of Drug Development
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Biopharmaceutical Manufacturing and Testing Technologies
    • 5.1.3.2. Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies
  • 5.2.2. Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations
  • 5.2.3. Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions
  • 5.2.4. Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Biopharmaceuticals Market, by Product Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Purified Proteins
• 6.4. Recombinant Growth Factors
• 6.5. Recombinant Hormone
• 6.6. Recombinant Proteins
• 6.7. Synthetic Immunomodulators
• 6.8. Vaccines

7. Biopharmaceuticals Market, by Services

• 7.1. Introduction
• 7.2. Compendial & Multi Compendial Laboratory Testing
• 7.3. Custom Testing or Customer Proprietary Testing
• 7.4. Laboratory Testing

8. Biopharmaceuticals Market, by Raw Material Type

• 8.1. Introduction
• 8.2. Active Pharmaceutical Ingredient
• 8.3. Formulation Excipients

9. Biopharmaceuticals Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Disorders
• 9.3. Cardiovascular Diseases
• 9.4. Hormonal Disorders
• 9.5. Immunology
• 9.6. Inflammatory & Infectious Diseases
• 9.7. Metabolic Disorders
• 9.8. Neurological Diseases
• 9.9. Oncology

10. Americas Biopharmaceuticals Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biopharmaceuticals Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceuticals Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
  • 13.3.2. LEQEMBI Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
  • 13.3.3. HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio